Literature DB >> 8136799

Quality of life of persons with onychomycosis.

D P Lubeck1, D L Patrick, P McNulty, S K Fifer, J Birnbaum.   

Abstract

Onychomycosis is a fungal infection of the nails which, although unsightly in appearance, is often considered to be a cosmetic problem. This research reports on the development and performance of a quality-of-life instrument to measure the impact of this disease on the patients' mental and general health, social functioning, pain, and self-confidence. In telephone interviews, 680 members of a health maintenance organization (299 with onychomycosis and 381 without) were asked a battery of items regarding quality of life (mental and social functioning, self-esteem, pain) and specific problems and symptoms related with one's nails. Persons with onychomycosis had significantly poorer ratings compared with the healthy persons with respect to general health (p = 0.02) and bodily pain p < 0.001). Persons with onychomycosis also had significantly (p < 0.05) poorer ratings for mental health, social functioning, health concern, physical appearance, and functional limitations associated with activities involving standing on one's feet or working with one's fingers. This study is the first to document the impact of onychomycosis on an individual's quality of life. Persons with onychomycosis may adapt to this condition, but they continue to experience embarrassment and discomfort that reduces their quality of life.

Entities:  

Mesh:

Year:  1993        PMID: 8136799     DOI: 10.1007/bf00449429

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  17 in total

Review 1.  GRISEOFULVIN: BIOLOGY AND CLINICAL USEFULNESS. A REVIEW.

Authors:  D W ANDERSON
Journal:  Ann Allergy       Date:  1965-02

Review 2.  Skin manifestations in AIDS patients.

Authors:  R Staughton
Journal:  Br J Clin Pract Suppl       Date:  1990-09

3.  Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis.

Authors:  A Y Finlay; G K Khan; D K Luscombe; M S Salek
Journal:  Br J Dermatol       Date:  1990-12       Impact factor: 9.302

Review 4.  Onychomycosis and terbinafine.

Authors: 
Journal:  Lancet       Date:  1990-03-17       Impact factor: 79.321

5.  Psoriasis--an index of disability.

Authors:  A Y Finlay; S E Kelly
Journal:  Clin Exp Dermatol       Date:  1987-01       Impact factor: 3.470

6.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

7.  Management of onychomycosis with oral terbinafine.

Authors:  N Zaias
Journal:  J Am Acad Dermatol       Date:  1990-10       Impact factor: 11.527

8.  Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent.

Authors:  R Arenas; G Fernández; L Domínguez
Journal:  Int J Dermatol       Date:  1991-08       Impact factor: 2.736

9.  Psychosocial management of patients with cutaneous cancers: a preliminary report.

Authors:  I Freidenbergs
Journal:  J Dermatol Surg Oncol       Date:  1981-10

10.  Life events and psychological distress in dermatologic disorders: psoriasis, chronic urticaria and fungal infections.

Authors:  G A Fava; G I Perini; P Santonastaso; C V Fornasa
Journal:  Br J Med Psychol       Date:  1980-09
View more
  25 in total

1.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.

Authors:  A G de Tiedra; J Mercadal; X Badía; J M Mascaró; R Lozano
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 2.  Onychomycosis. Going for cure.

Authors:  A K Gupta; N H Shear
Journal:  Can Fam Physician       Date:  1997-02       Impact factor: 3.275

3.  A health-related quality of life measure for use in patients with onychomycosis: a validation study.

Authors:  D P Lubeck; D Gause; J R Schein; L E Prebil; L P Potter
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

Review 4.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

5.  Cost of treatment for onychomycosis. Data from a 9-month observational study.

Authors:  D M Stier; C Henke; J Schein; J Doyle; W H Schonfeld; J Broering
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 7.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

8.  Quality of life bibliography and indexes: 1993 update.

Authors:  R A Berzon; G P Simeon; R L Simpson; M A Donnelly; H H Tilson
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

Review 9.  The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

10.  Evaluation of clinicomycological aspects of onychomycosis.

Authors:  Ravinder Kaur; Bineeta Kashyap; Rati Makkar
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.